Heron Therapeutics Company Profile (NASDAQ:HRTX)

Analyst Ratings

Consensus Ratings for Heron Therapeutics (NASDAQ:HRTX) (?)
Ratings Breakdown: 9 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $51.44 (208.98% upside)

Analysts' Ratings History for Heron Therapeutics (NASDAQ:HRTX)
Show:
DateFirmActionRatingPrice TargetActions
7/9/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/27/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2016Cantor FitzgeraldReiterated RatingBuy$41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Brean CapitalReiterated RatingBuy$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016Noble FinancialReiterated RatingBuy$51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/15/2016Lake Street CapitalReiterated RatingBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2015JMP SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2015Bank of America Corp.Boost Price TargetBuy$54.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Heron Therapeutics (NASDAQ:HRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/5/2016        
5/5/2016Q1($0.92)($0.92)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2016Q4($0.64)($0.87)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2015Q3($0.67)($0.63)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2015($0.65)($0.74)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015Q115($0.68)($0.70)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2015($0.79)($0.71)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014($0.69)($0.66)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2014($0.62)($0.78)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.67)($0.74)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014($0.53)($0.75)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Heron Therapeutics (NASDAQ:HRTX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.21)($0.90)($1.06)
Q2 20163($0.98)($0.92)($0.95)
Q3 20163($0.92)($0.83)($0.87)
Q4 20163($0.91)($0.75)($0.81)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Heron Therapeutics (NASDAQ:HRTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Heron Therapeutics (NASDAQ:HRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/21/2016Robert RosenPresidentSell200,000$23.23$4,646,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Kevin C TangDirectorBuy121,212$24.75$2,999,997.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2015Kevin C TangDirectorBuy150,000$20.62$3,093,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Kimberly ManhardDirectorSell2,708$21.17$57,328.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2014Barry D QuartCEOBuy10,000$11.75$117,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2014Kevin C TangDirectorBuy510,638$11.75$5,999,996.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Barry D QuartCEOBuy1,000,000$0.40$400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Heron Therapeutics (NASDAQ:HRTX)
DateHeadline
07/22/16 04:27 PMSlingshot Insights Expert Discusses Sustol Delays
07/22/16 07:27 AMNew Broker Ratings For Heron Therapeutics Inc (HRTX) - FTSE News
07/21/16 04:41 PMHeron Therapeutics Inc (HRTX) Drops 6.3% on July 19
07/21/16 10:32 AMHeron Therapeutics, Inc. (NASDAQ:HRTX): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 10:32 AMWhat's in Heron Therapeutics Inc After Today's Huge Increase? - Consumer Eagle
07/21/16 10:32 AMHeron Therapeutics Inc (HRTX) Drops 6.3% on July 19 - Equities.com
07/20/16 02:29 PMWill Heron Therapeutics Inc Go Down Anytime Soon? - Press Telegraph
07/20/16 07:26 AMHeightened Volatility Spotted on Shares of: Heron Therapeutics, Inc. (NASDAQ:HRTX) - Engelwood Daily
07/20/16 07:26 AMHeron Therapeutics Inc Realized Volatility Hits Elevated Level - CML News
07/20/16 07:26 AMIs $55 Price Target Attainable For Heron Therapeutics, Inc. (NASDAQ:HRTX)? - Investor Newswire
07/20/16 07:26 AMEquity Roundup: Stock Performance Focus on Heron Therapeutics, Inc. (NASDAQ:HRTX) - Press Telegraph
07/18/16 04:42 PMHow Analysts Feel About Heron Therapeutics Inc (NASDAQ:HRTX)? - Consumer Eagle
07/18/16 04:42 PMHeron Therapeutics Has An Upcoming Approval - Seeking Alpha
07/17/16 08:55 AMShares Moving Down on the Week: Heron Therapeutics, Inc. (NASDAQ:HRTX) - Engelwood Daily
07/16/16 07:54 AMShares Experiencing a Downtrend: Heron Therapeutics, Inc. (NASDAQ:HRTX) - TGP
07/15/16 03:34 PMHeron Therapeutics Inc (HRTX) Drops 7.27% on July 13
07/15/16 07:49 AMHeron Therapeutics Incorporated (NASDAQ:HRTX) Shorts Decreased by 1.02% After Short Covering - Press Telegraph
07/15/16 07:49 AMBroadfin Capital LLC Decreased Stake in Heron Therapeutics INC (NASDAQ:HRTX) by $13.80 Million as Shares ... - Consumer Eagle
07/15/16 07:49 AMHeron Therapeutics Inc (HRTX) Drops 7.27% on July 13 - Equities.com
07/14/16 04:38 PMHeron Therapeutics, Inc. (NASDAQ:HRTX) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 07:59 AMShares Losing Ground for the Month; Investor Alert on Heron Therapeutics, Inc. (NASDAQ:HRTX) - Engelwood Daily
07/14/16 07:59 AMAnalyst Target and Average Rating Watch: Heron Therapeutics, Inc. (NASDAQ:HRTX) - Press Telegraph
07/13/16 07:24 AMHeron Therapeutics, Inc. (NASDAQ:HRTX) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 07:24 AMStrong Sell Calls For Heron Therapeutics, Inc. (NASDAQ:HRTX) At 0 - Investor Newswire
07/08/16 04:36 PMHeron Therapeutics, Inc. Stock Momentum Hits Extreme Weakness - CML News
07/08/16 07:20 AMCan Heron Therapeutics, Inc. (NASDAQ:HRTX) Improve on the Earnings Front? - Engelwood Daily
07/08/16 05:58 AMAdam Feuerstein's Biotech Stock Mailbag: Heron, Exelixis -
07/07/16 04:33 PMNoteworthy Wednesday Option Activity: HRTX, TSO, PAY
07/07/16 07:21 AMCompany Stock Focus for Heron Therapeutics, Inc. (NASDAQ:HRTX): Which Way Will Shares Head? - Press Telegraph
07/06/16 04:42 PMHeron Therapeutics, Inc. (NASDAQ:HRTX) Expected to Reach Highs Of $55 - Investor Newswire
07/06/16 04:42 PMIs Heron Therapeutics Inc a Sell? The Stock Declines Again - Engelwood Daily
07/06/16 04:42 PMInsiders are Gradually Selling Heron Therapeutics, Inc. (NASDAQ:HRTX) - Telanagana Press
07/05/16 04:24 PMThis Weeks Broker Price Targets For Heron Therapeutics Inc (HRTX) - Fiscal Standard
07/01/16 07:18 AMCovering the Bases on Heron Therapeutics, Inc. (NASDAQ:HRTX): Where is the Stock Going? - Press Telegraph
06/30/16 07:21 AMHeron Therapeutics Inc (HRTX) Current Analyst Ratings - Fiscal Standard
06/30/16 07:21 AMHeron Therapeutics Inc (HRTX) Updated Price Targets - FTSE News
06/27/16 08:50 AMHeron Therapeutics Inc (HRTX) Broker Price Targets For The Coming Week - Fiscal Standard
06/24/16 07:06 AMBroadfin Capital LLC Decreased Stake in Heron Therapeutics INC (NASDAQ:HRTX) by $13.80 Million as Shares ... - Press Telegraph
06/22/16 04:35 PMCompany Update (NASDAQ:HRTX): Heron Therapeutics Inc Announces Appointment of Christian Waage to Board of ... - Smarter Analyst
06/22/16 03:16 PMHERON THERAPEUTICS, INC. /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to -
06/22/16 07:29 AMHeron Therapeutics Announces Appointment of Christian Waage to Board of Directors - [at noodls] - REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 22, 2016-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that ...
06/21/16 04:12 PMStrong Buy Calls Count For Heron Therapeutics, Inc. (NASDAQ:HRTX) At 9 - Investor Newswire
06/20/16 10:42 AMHeron Therapeutics, Inc. Stock Momentum Hits Weakness - CML News
06/16/16 04:29 PMRecently Issued Stock Ratings For Heron Therapeutics Inc (HRTX) - Fiscal Standard
06/14/16 04:21 PMTrend Of Rating Given To Heron Therapeutics, Inc. (NASDAQ:HRTX) - Investor Newswire
06/07/16 04:40 PMHeron Therapeutics Inc (HRTX) Jumps 5.35% on June 06 - Equities.com
06/05/16 07:10 AMAre Analysts Bearish Heron Therapeutics Inc (NASDAQ:HRTX) After Last Week? - HNN
06/04/16 07:12 AMHealthcare Trading Stocks: Heron Therapeutics, Inc. (NASDAQ:HRTX) , Apricus Biosciences, Inc (NASDAQ:APRI) - Is stories
06/02/16 07:14 AMTarget Price and Stock Performance Rundown for Heron Therapeutics, Inc. (NASDAQ:HRTX) - HNN - Target Price and Stock Performance Rundown for Heron Therapeutics, Inc. (NASDAQ:HRTX)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Heron Therapeutics, Inc. (NASDAQ ...and more »
06/02/16 07:14 AMBroker Watchlist: Heron Therapeutics Inc (HRTX) - Share Trading News - Broker Watchlist: Heron Therapeutics Inc (HRTX)Share Trading News09/23/2015 – Heron Therapeutics Inc had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 58 price target on the stock. The share price of Heron Therapeutics Inc (HRTX) was down -3.18% during the last trading session, with a day ...and more »

Social

About Heron Therapeutics

Heron Therapeutics logoHeron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: HRTX
  • CUSIP:
Key Metrics:
  • Previous Close: $16.19
  • 50 Day Moving Average: $18.02
  • 200 Day Moving Average: $19.33
  • P/E Ratio: N/A
  • P/E Growth: -0.03
  • Market Cap: $N/A
  • Beta: 1.3
  • Current Year EPS Consensus Estimate: $-3.54 EPS
  • Next Year EPS Consensus Estimate: $-1.62 EPS
Additional Links:
Heron Therapeutics (NASDAQ:HRTX) Chart for Saturday, July, 23, 2016